# Surgery Partners, Inc.: financial statements, quarterly

SGRY · Nasdaq · CIK 1638833 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sgry.md) · [Financials](/companies/sgry/financials.md) · [Filings](/companies/sgry/filings.md) · [Insiders](/companies/sgry/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sgry/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [674](/filings/0001638833-24-000147.md) | [735 d](/filings/0001638833-26-000008.md) | [717](/filings/0001638833-25-000092.md) | [762](/filings/0001638833-25-000136.md) | [770](/filings/0001638833-25-000163.md) | [864 d](/filings/0001638833-26-000008.md) | [776](/filings/0001638833-26-000046.md) | [826](/filings/0001638833-26-000077.md) | [822](/filings/0001638833-25-000163.md) | [885 d](/filings/0001638833-26-000008.md) | [811](/filings/0001638833-26-000046.md) | [849](/filings/0001638833-26-000077.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [82.6](/filings/0001638833-24-000147.md) | [101 d](/filings/0001638833-26-000008.md) | [76.0](/filings/0001638833-25-000092.md) | [84.8](/filings/0001638833-25-000136.md) | [60.9](/filings/0001638833-25-000163.md) | [127 d](/filings/0001638833-26-000008.md) | [61.9](/filings/0001638833-26-000046.md) | [112](/filings/0001638833-26-000077.md) | [106](/filings/0001638833-25-000163.md) | [110 d](/filings/0001638833-26-000008.md) | [65.8](/filings/0001638833-26-000046.md) | [102](/filings/0001638833-26-000077.md) |
| Income tax | $m | [3.1](/filings/0001638833-24-000147.md) | [6.0 d](/filings/0001638833-26-000008.md) | [4.4](/filings/0001638833-25-000092.md) | [4.9](/filings/0001638833-25-000136.md) | [4.5](/filings/0001638833-25-000163.md) | [121 d](/filings/0001638833-26-000008.md) | [0.0](/filings/0001638833-26-000046.md) | [(1.1)](/filings/0001638833-26-000077.md) | [5.5](/filings/0001638833-25-000163.md) | [13.6 d](/filings/0001638833-26-000008.md) | [(1.2)](/filings/0001638833-26-000046.md) | [2.6](/filings/0001638833-26-000077.md) |
| Net income | $m | [(4.9)](/filings/0001638833-24-000147.md) | [(1.0) d](/filings/0001638833-26-000008.md) | [(12.4)](/filings/0001638833-25-000092.md) | [(15.5)](/filings/0001638833-25-000136.md) | [(31.7)](/filings/0001638833-25-000163.md) | [(109) d](/filings/0001638833-26-000008.md) | [(37.7)](/filings/0001638833-26-000046.md) | [(2.5)](/filings/0001638833-26-000077.md) | [(22.7)](/filings/0001638833-25-000163.md) | [(15.0) d](/filings/0001638833-26-000008.md) | [(35.9)](/filings/0001638833-26-000046.md) | [(15.0)](/filings/0001638833-26-000077.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001638833-24-000147.md) | not reported | [(0.10)](/filings/0001638833-25-000092.md) | [(0.12)](/filings/0001638833-25-000136.md) | [(0.25)](/filings/0001638833-25-000163.md) | not reported | [(0.30)](/filings/0001638833-26-000046.md) | [(0.02)](/filings/0001638833-26-000077.md) | [(0.18)](/filings/0001638833-25-000163.md) | not reported | [(0.28)](/filings/0001638833-26-000046.md) | [(0.12)](/filings/0001638833-26-000077.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0001638833-24-000147.md) | not reported | [(0.10)](/filings/0001638833-25-000092.md) | [(0.12)](/filings/0001638833-25-000136.md) | [(0.25)](/filings/0001638833-25-000163.md) | not reported | [(0.30)](/filings/0001638833-26-000046.md) | [(0.02)](/filings/0001638833-26-000077.md) | [(0.18)](/filings/0001638833-25-000163.md) | not reported | [(0.28)](/filings/0001638833-26-000046.md) | [(0.12)](/filings/0001638833-26-000077.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [236](/filings/0001638833-23-000097.md) | [196](/filings/0001638833-25-000053.md) | [185](/filings/0001638833-24-000113.md) | [214](/filings/0001638833-24-000135.md) | [222](/filings/0001638833-24-000147.md) | [270](/filings/0001638833-26-000008.md) | [229](/filings/0001638833-25-000092.md) | [250](/filings/0001638833-25-000136.md) | [203](/filings/0001638833-25-000163.md) | [240](/filings/0001638833-26-000077.md) | [182](/filings/0001638833-26-000046.md) | [217](/filings/0001638833-26-000077.md) |
| Current assets | $m | [876](/filings/0001638833-23-000097.md) | [895](/filings/0001638833-25-000053.md) | [896](/filings/0001638833-24-000113.md) | [1,013](/filings/0001638833-24-000135.md) | [1,036](/filings/0001638833-24-000147.md) | [1,119](/filings/0001638833-26-000008.md) | [1,075](/filings/0001638833-25-000092.md) | [1,105](/filings/0001638833-25-000136.md) | [1,102](/filings/0001638833-25-000163.md) | [1,151](/filings/0001638833-26-000077.md) | [1,083](/filings/0001638833-26-000046.md) | [1,126](/filings/0001638833-26-000077.md) |
| Total assets | $m | [6,780](/filings/0001638833-23-000097.md) | [6,877](/filings/0001638833-25-000053.md) | [6,976](/filings/0001638833-24-000113.md) | [7,489](/filings/0001638833-24-000135.md) | [7,534](/filings/0001638833-24-000147.md) | [7,890](/filings/0001638833-26-000008.md) | [7,949](/filings/0001638833-25-000092.md) | [7,955](/filings/0001638833-25-000136.md) | [7,947](/filings/0001638833-25-000163.md) | [8,120](/filings/0001638833-26-000077.md) | [8,042](/filings/0001638833-26-000046.md) | [8,050](/filings/0001638833-26-000077.md) |
| Current liabilities | $m | [501](/filings/0001638833-23-000097.md) | [523](/filings/0001638833-25-000053.md) | [523](/filings/0001638833-24-000113.md) | [552](/filings/0001638833-24-000135.md) | [575](/filings/0001638833-24-000147.md) | [624](/filings/0001638833-26-000008.md) | [569](/filings/0001638833-25-000092.md) | [573](/filings/0001638833-25-000136.md) | [586](/filings/0001638833-25-000163.md) | [616](/filings/0001638833-26-000077.md) | [582](/filings/0001638833-26-000046.md) | [579](/filings/0001638833-26-000077.md) |
| Long-term debt | $m | not reported | [2,804](/filings/0001638833-24-000029.md) | not reported | not reported | not reported | [3,405](/filings/0001638833-25-000053.md) | not reported | not reported | not reported | [3,735](/filings/0001638833-26-000008.md) | not reported | not reported |
| Shareholders' equity | $m | [2,005](/filings/0001638833-23-000097.md) | [1,987](/filings/0001638833-25-000053.md) | [1,967](/filings/0001638833-24-000113.md) | [1,952](/filings/0001638833-24-000135.md) | [1,897](/filings/0001638833-24-000147.md) | [1,790](/filings/0001638833-26-000008.md) | [1,740](/filings/0001638833-25-000092.md) | [1,748](/filings/0001638833-25-000136.md) | [1,730](/filings/0001638833-25-000163.md) | [1,713](/filings/0001638833-26-000077.md) | [1,688](/filings/0001638833-26-000046.md) | [1,671](/filings/0001638833-26-000077.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [105 d](/filings/0001638833-24-000147.md) | [62.6 d](/filings/0001638833-26-000008.md) | [40.7](/filings/0001638833-25-000092.md) | [82.8 d](/filings/0001638833-25-000136.md) | [65.2 d](/filings/0001638833-25-000163.md) | [111 d](/filings/0001638833-26-000008.md) | [6.0](/filings/0001638833-26-000046.md) | [81.3 d](/filings/0001638833-26-000077.md) | [83.6 d](/filings/0001638833-25-000163.md) | [103 d](/filings/0001638833-26-000008.md) | [11.7](/filings/0001638833-26-000046.md) | [59.3 d](/filings/0001638833-26-000077.md) |
| Capital expenditure | $m | [18.9 d](/filings/0001638833-24-000147.md) | [19.8 d](/filings/0001638833-26-000008.md) | [21.0](/filings/0001638833-25-000092.md) | [26.9 d](/filings/0001638833-25-000136.md) | [20.2 d](/filings/0001638833-25-000163.md) | [22.3 d](/filings/0001638833-26-000008.md) | [22.7](/filings/0001638833-26-000046.md) | [23.4 d](/filings/0001638833-26-000077.md) | [19.8 d](/filings/0001638833-25-000163.md) | [12.8 d](/filings/0001638833-26-000008.md) | [16.0](/filings/0001638833-26-000046.md) | [21.8 d](/filings/0001638833-26-000077.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [88.9](/filings/0001638833-23-000097.md) | [125](/filings/0001638833-24-000113.md) | [127](/filings/0001638833-24-000135.md) | [126](/filings/0001638833-24-000147.md) | [126](/filings/0001638833-25-000092.md) | [126](/filings/0001638833-25-000136.md) | [126](/filings/0001638833-25-000163.md) | [127](/filings/0001638833-26-000046.md) | [127](/filings/0001638833-26-000077.md) | [127](/filings/0001638833-25-000163.md) | [128](/filings/0001638833-26-000046.md) | [129](/filings/0001638833-26-000077.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 130,918,260 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001638833-26-000077.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.